# Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

> **NCT07511023** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (estimated)

## Conditions studied

- Phase 2
- Sacituzumab Tirumotecan
- Refractory Metastatic
- Unresectable Squamous
- Cell Carcinoma of the Anus/ Rectum

## Interventions

- **DRUG:** Sacituzumab Tirumotecan

## Key facts

- **NCT ID:** NCT07511023
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-25
- **Primary completion:** 2031-03-01
- **Final completion:** 2033-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07511023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07511023, "Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07511023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*